Covered recipient · General Payments record
HENRY HOLLAND
General Payments · PY2018–2024
$2,844.34
- Reported across 65 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $135.65 | 6 |
| Education | $39.98 | 2 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Celgene Corporation | $45.92 | 2 |
| Kite Pharma, Inc. | $39.98 | 2 |
| Takeda Pharmaceuticals U.S.A., Inc. | $27.03 | 1 |
| ABBVIE INC. | $22.86 | 1 |
| Lilly USA, LLC | $21.59 | 1 |
| GlaxoSmithKline, LLC. | $18.25 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (8)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $22.86 | 10/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103930800 | CMS |
| Celgene Corporation | $23.18 | 06/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101186531 | CMS |
| Celgene Corporation | $22.74 | 10/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101186543 | CMS |
| GlaxoSmithKline, LLC. | $18.25 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116042952 | CMS |
| Kite Pharma, Inc. | $19.99 | 08/19/2024 | Education | Undisputed | 01/23/2026 | 1128610769 | CMS |
| Kite Pharma, Inc. | $19.99 | 08/19/2024 | Education | Undisputed | 01/23/2026 | 1128610771 | CMS |
| Lilly USA, LLC | $21.59 | 04/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135000154 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $27.03 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144959192 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.